Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Getting to 90-90-90 in paediatric HIV: What is needed?

Davies MA, Pinto J, Bras M.

J Int AIDS Soc. 2015 Dec 2;18(7Suppl 6):20770. doi: 10.7448/IAS.18.7.20770. eCollection 2015. No abstract available.

2.

Option B+ for prevention of vertical HIV transmission has no influence on adverse birth outcomes in a cross-sectional cohort in Western Uganda.

Rempis EM, Schnack A, Decker S, Braun V, Rubaihayo J, Tumwesigye NM, Busingye P, Harms G, Theuring S.

BMC Pregnancy Childbirth. 2017 Mar 7;17(1):82. doi: 10.1186/s12884-017-1263-2.

3.

Evaluation of Medication-mediated Effects in Pharmacoepidemiology.

Tchetgen Tchetgen EJ, Phiri K.

Epidemiology. 2017 May;28(3):439-445. doi: 10.1097/EDE.0000000000000610.

4.

Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial.

Siou K, Walmsley SL, Murphy KE, Raboud J, Loutfy M, Yudin MH, Silverman M, Ladhani NN, Serghides L.

Pilot Feasibility Stud. 2016 Aug 12;2:49. eCollection 2016. Erratum in: Pilot Feasibility Stud. 2017 Apr 28;3:21.

5.

PMTCT Option B+ Does Not Increase Preterm Birth Risk and May Prevent Extreme Prematurity: A Retrospective Cohort Study in Malawi.

Chagomerana MB, Miller WC, Pence BW, Hosseinipour MC, Hoffman IF, Flick RJ, Tweya H, Mumba S, Chimbwandira F, Powers KA.

J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):367-374. doi: 10.1097/QAI.0000000000001253.

PMID:
27875363
6.

Perinatal Antiretroviral Exposure and Prevented Mother-to-child HIV Infections in the Era of Antiretroviral Prophylaxis in the United States, 1994-2010.

Little KM, Taylor AW, Borkowf CB, Mendoza MC, Lampe MA, Weidle PJ, Nesheim SR.

Pediatr Infect Dis J. 2017 Jan;36(1):66-71.

PMID:
27749662
7.

Disclosing in utero HIV/ARV exposure to the HIV-exposed uninfected adolescent: is it necessary?

Jao J, Hazra R, Mellins CA, Remien RH, Abrams EJ.

J Int AIDS Soc. 2016 Oct 13;19(1):21099. doi: 10.7448/IAS.19.1.21099. eCollection 2016.

8.

Increasing Number and Proportion of Adverse Obstetrical Outcomes among Women Living with HIV in the Ottawa Area: A 20-Year Clinical Case Series.

Buchan S, Muldoon KA, Spaans JN, Balfour L, Samson L, Walker M, Cameron DW.

Can J Infect Dis Med Microbiol. 2016;2016:1546365. doi: 10.1155/2016/1546365. Epub 2016 Jul 27.

9.

Management of HIV Infection during Pregnancy in the United States: Updated Evidence-Based Recommendations and Future Potential Practices.

Rimawi BH, Haddad L, Badell ML, Chakraborty R.

Infect Dis Obstet Gynecol. 2016;2016:7594306. doi: 10.1155/2016/7594306. Epub 2016 Jul 18. Review.

10.

Multiple Overimputation to Address Missing Data and Measurement Error: Application to HIV Treatment During Pregnancy and Pregnancy Outcomes.

Bengtson AM, Westreich D, Musonda P, Pettifor A, Chibwesha C, Chi BH, Vwalika B, Pence BW, Stringer JS, Miller WC.

Epidemiology. 2016 Sep;27(5):642-50. doi: 10.1097/EDE.0000000000000494.

PMID:
27054651
11.
12.

Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa.

Moodley T, Moodley D, Sebitloane M, Maharaj N, Sartorius B.

BMC Pregnancy Childbirth. 2016 Feb 11;16:35. doi: 10.1186/s12884-016-0821-3.

14.

Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.

Papp E, Balogun K, Banko N, Mohammadi H, Loutfy M, Yudin MH, Shah R, MacGillivray J, Murphy KE, Walmsley SL, Silverman M, Serghides L.

J Infect Dis. 2016 May 15;213(10):1532-40. doi: 10.1093/infdis/jiw004. Epub 2016 Jan 5.

15.

The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children.

Vreeman RC, Scanlon ML, McHenry MS, Nyandiko WM.

J Int AIDS Soc. 2015 Dec 2;18(Suppl 6):20258. doi: 10.7448/IAS.18.7.20258. eCollection 2015.

16.

Duration of cART Before Delivery and Low Infant Birthweight Among HIV-Infected Women in Lusaka, Zambia.

Bengtson AM, Chibwesha CJ, Westreich D, Mubiana-Mbewe M, Vwalika B, Miller WC, Mapani M, Musonda P, Pettifor A, Chi BH.

J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):563-9. doi: 10.1097/QAI.0000000000000909.

17.

The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations.

Duryea E, Nicholson F, Cooper S, Roberts S, Rogers V, McIntire D, Sheffield J, Stewart R.

Infect Dis Obstet Gynecol. 2015;2015:563727. doi: 10.1155/2015/563727. Epub 2015 Nov 5.

18.

Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry.

Vannappagari V, Koram N, Albano J, Tilson H, Gee C.

BJOG. 2016 May;123(6):910-6. doi: 10.1111/1471-0528.13542. Epub 2015 Aug 12.

19.

Evidence of Subclinical mtDNA Alterations in HIV-Infected Pregnant Women Receiving Combination Antiretroviral Therapy Compared to HIV-Negative Pregnant Women.

Money DM, Wagner EC, Maan EJ, Chaworth-Musters T, Gadawski I, van Schalkwyk JE, Forbes JC, Burdge DR, Albert AY, Lohn Z, Côté HC; Oak Tree Clinic Research Group.

PLoS One. 2015 Aug 6;10(8):e0135041. doi: 10.1371/journal.pone.0135041. eCollection 2015.

20.

Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?

Kakkar F, Boucoiran I, Lamarre V, Ducruet T, Amre D, Soudeyns H, Lapointe N, Boucher M.

J Int AIDS Soc. 2015 Jun 5;18:19933. doi: 10.7448/IAS.18.1.19933. eCollection 2015.

Supplemental Content

Support Center